SAB Biotherapeutics, Inc. (SABS)

In the past six months, SAB Biotherapeutics' stock price has been impacted by several events. Positive Phase 1 trial results for SAB-142 were announced on December 17, 2025. The company launched a $75 million ATM program on December 29, 2025. UBS Group upgraded its rating for SABS to "strong-buy" on January 8, 2026, and Guggenheim initiated coverage with a "Buy" recommendation on December 19, 2025, while Chardan Capital maintained a "Buy" recommendation on December 18, 2025. The first patient was dosed in SAB BIO's SAFEGUARD clinical trial of SAB-142 for Stage 3 T1D on December 18, 2025. Over the last month, the stock price decreased by 1.84%, and over the last 12 months, it decreased by 2.60%, but between January 6, 2025, and January 5, 2026, the share price increased by 6.25%, closing at $3.68 as of January 9, 2026.

The demand for SAB Biotherapeutics' products and services is primarily driven by disease prevalence, clinical trial outcomes, regulatory approvals, and market adoption of new therapies, rather than traditional consumer-driven seasonal patterns. While influenza has seasonal outbreaks, the development and demand for a therapeutic like SAB-176 would be more tied to the severity and spread of the virus.

SAB Biotherapeutics, Inc., now operating as SAB BIO, is a clinical-stage biopharmaceutical company focused on developing immunotherapies using fully human polyclonal antibodies, utilizing its proprietary DiversitAb™ platform. The company's major product candidates include SAB-142, a human, multi-target anti-thymocyte globulin treatment currently in Phase 2b clinical trials for delaying the onset or progression of Type 1 Diabetes and also in development for organ transplant induction/rejection; SAB-185, a fully-human polyclonal antibody therapeutic candidate in Phase III clinical trials for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza.

SAB Biotherapeutics, Inc. is headquartered in Miami Beach, Florida, and was founded in 2014, previously based in Sioux Falls, South Dakota, indicating a primary operational focus within the United States.

SAB Biotherapeutics has actively managed its brand and reputation over the past year. In June 2024, the company rebranded to "SAB BIO" with new name, logo, and website updates, while retaining the SABS ticker symbol, emphasizing its focus on unmet needs in Type 1 Diabetes. On January 7, 2026, SAB BIO announced the appointment of a new Chair and a new Director to its Board. The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in January 2026 and has presented at other major conferences. Multiple analyst firms have initiated or maintained "Buy" or "Strong Buy" ratings for SABS in late 2025 and early 2026.

SAB Biotherapeutics, Inc. has significant institutional and individual ownership. Institutional investors hold approximately 58.87% to 59.29% of the stock, with major owners including Vivo Capital, LLC, Commodore Capital Lp, and Ra Capital Management, L.p. Insider ownership is substantial, around 64.92%, with key individual insider owners including Christine E. Hamilton, Edward D. Hamilton, and Andrew Moin.